Efficacy and safety profile of moxifloxacin in treatment of urogenital system infections: A meta-analysis of randomized controlled trials

higher than conventional therapy [RR = 1.08, 95%CI (1.02, 1.14), P = 0.008; RR = 1.09, 95%CI (1.04, 1.14), P = 0.0005; RR = 1.04, 95%CI (0.99, 1.09), P = 0.08]; the incidences of adverse drug reactions between moxifloxacin and control group were not statistically significant [RR = 0.88, 95%CI (0.72, 1.06), P = 0.17]. In three large studies of pelvic inflammatory disease (PID) patients, no statistically significant difference was found between moxifloxacin monotherapy group and control group about clinical cure rates, microbiological success rates and the incidences of adverse drug reactions [RR = 0.98, 95%CI (0.95, 1.02), P = 0.33; RR = 1.06, 95%CI (0.96, 1.16), P = 0.25; RR = 0.85, 95%CI (0.68, 1.05), P = 0.13]. Moxifloxacin can be suggested as the regimen of choice for treatment of urogenital system infections.